Along similar lines, chimeric antigen receptor T (CAR-T) cells engineered to bind a distal epitope of CD22 less efficiently kill cancer cells compared to CAR-T cells targeting a CD22 proximal epitope153. The gene discussed is CD22; the disease is cancer.